Literature DB >> 28695236

Volumetric parameters on FDG PET can predict early intrahepatic recurrence-free survival in patients with hepatocellular carcinoma after curative surgical resection.

Jeong Won Lee1, Sang Hyun Hwang2, Hyun Jeong Kim2, Dongwoo Kim2, Arthur Cho2, Mijin Yun3.   

Abstract

PURPOSE: This study assessed the prognostic values of volumetric parameters on 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) in predicting early intrahepatic recurrence-free survival (RFS) after curative resection in patients with hepatocellular carcinoma (HCC).
METHODS: A retrospective analysis was performed on 242 patients with HCC who underwent staging FDG PET and subsequent curative surgical resection. The tumor-to-non-tumorous liver uptake ratio, metabolic tumor volume (MTV), and total lesion glycolysis (TLG) of the HCC lesions on PET were measured. The prognostic values of clinical factors and PET parameters for predicting overall RFS, overall survival (OS), extrahepatic RFS, and early and late intrahepatic RFS were assessed.
RESULTS: The median follow-up period was 54.7 months, during which 110 patients (45.5%) experienced HCC recurrence and 62 (25.6%) died. Patients with extrahepatic and early intrahepatic recurrence showed worse OS than did those with no recurrence or late intrahepatic recurrence (p < 0.001). Serum bilirubin level, MTV, and TLG were independent prognostic factors for overall RFS and OS (p < 0.05). Only MTV and TLG were prognostic for extrahepatic RFS (p < 0.05). Serum alpha-fetoprotein and bilirubin levels, MTV, and TLG were prognostic for early intrahepatic RFS (p < 0.05) and hepatitis C virus (HCV) positivity and serum albumin level were independently prognostic for late intrahepatic RFS (p < 0.05).
CONCLUSION: Intrahepatic recurrence showed different prognoses according to the time interval of recurrence in which early recurrence had as poor survival as extrahepatic recurrence. MTV and TLG on initial staging PET were significant independent factors for predicting early intrahepatic and extrahepatic RFS in patients with HCC after curative resection. Only HCV positivity and serum albumin level were significant for late intrahepatic RFS, which is mainly attributable to the de novo formation of new primary HCC.

Entities:  

Keywords:  FDG PET; Hepatocellular carcinoma; Metabolic tumor volume; Prognosis; Recurrence

Mesh:

Substances:

Year:  2017        PMID: 28695236     DOI: 10.1007/s00259-017-3764-7

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  32 in total

Review 1.  Management of HCC.

Authors:  Carlos Rodríguez de Lope; Silvia Tremosini; Alejandro Forner; María Reig; Jordi Bruix
Journal:  J Hepatol       Date:  2012       Impact factor: 25.083

2.  Prediction of Posttransplantation Recurrence of Hepatocellular Carcinoma Using Metabolic and Volumetric Indices of 18F-FDG PET/CT.

Authors:  Yong-Il Kim; Jin Chul Paeng; Gi Jeong Cheon; Kyung-Suk Suh; Dong Soo Lee; June-Key Chung; Keon Wook Kang
Journal:  J Nucl Med       Date:  2016-03-16       Impact factor: 10.057

3.  The role of preoperative [18F]fluorodeoxyglucose positron emission tomography in predicting early recurrence after curative resection of hepatocellular carcinomas.

Authors:  Sung Gwe Ahn; Sung Hoon Kim; Tae Joo Jeon; Ho Jin Cho; Sae Byeol Choi; Mi Jin Yun; Jong Doo Lee; Kyung Sik Kim
Journal:  J Gastrointest Surg       Date:  2011-09-09       Impact factor: 3.452

4.  Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors.

Authors:  Koji Uchino; Ryosuke Tateishi; Shuichiro Shiina; Miho Kanda; Ryota Masuzaki; Yuji Kondo; Tadashi Goto; Masao Omata; Haruhiko Yoshida; Kazuhiko Koike
Journal:  Cancer       Date:  2011-03-22       Impact factor: 6.860

5.  The predictive value of metabolic tumor volume on FDG PET/CT for transarterial chemoembolization and transarterial chemotherapy infusion in hepatocellular carcinoma patients without extrahepatic metastasis.

Authors:  Jeong Won Lee; Mijin Yun; Arthur Cho; Kwang-Hyub Han; Do Young Kim; Sang Mi Lee; Jong Doo Lee
Journal:  Ann Nucl Med       Date:  2015-02-05       Impact factor: 2.668

6.  Clinical characteristics and prognostic factors for advanced hepatocellular carcinoma with extrahepatic metastasis.

Authors:  Hajime Aino; Shuji Sumie; Takashi Niizeki; Ryoko Kuromatsu; Nobuyoshi Tajiri; Masahito Nakano; Manabu Satani; Shingo Yamada; Shusuke Okamura; Shigeo Shimose; Hiroaki Sumie; Takuji Torimura; Michio Sata
Journal:  Mol Clin Oncol       Date:  2014-02-14

7.  Harmonizing SUVs in multicentre trials when using different generation PET systems: prospective validation in non-small cell lung cancer patients.

Authors:  Charline Lasnon; Cédric Desmonts; Elske Quak; Radj Gervais; Pascal Do; Catherine Dubos-Arvis; Nicolas Aide
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-04-06       Impact factor: 9.236

8.  In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET.

Authors:  T Torizuka; N Tamaki; T Inokuma; Y Magata; S Sasayama; Y Yonekura; A Tanaka; Y Yamaoka; K Yamamoto; J Konishi
Journal:  J Nucl Med       Date:  1995-10       Impact factor: 10.057

9.  Impact of the EARL harmonization program on automatic delineation of metabolic active tumour volumes (MATVs).

Authors:  Charline Lasnon; Blandine Enilorac; Hosni Popotte; Nicolas Aide
Journal:  EJNMMI Res       Date:  2017-03-31       Impact factor: 3.138

10.  A randomised controlled trial of meloxicam, a Cox-2 inhibitor, to prevent hepatocellular carcinoma recurrence after initial curative treatment.

Authors:  Yuko Takami; Susumu Eguchi; Masaki Tateishi; Tomoki Ryu; Kazuhiro Mikagi; Yoshiyuki Wada; Hideki Saitsu
Journal:  Hepatol Int       Date:  2016-02-04       Impact factor: 6.047

View more
  4 in total

1.  Predicting tumor recurrence using metabolic indices of 18F-FDG PET/CT prior to orthotopic liver transplantationfor hepatocellular carcinoma.

Authors:  Enci Ding; Dongyan Lu; Lijuan Wei; Xuemin Feng; Jie Shen; Wengui Xu
Journal:  Oncol Lett       Date:  2020-05-28       Impact factor: 2.967

2.  [18F]FDG uptake of bone marrow on PET/CT for predicting distant recurrence in breast cancer patients after surgical resection.

Authors:  Jeong Won Lee; Sung Yong Kim; Sun Wook Han; Jong Eun Lee; Hyun Ju Lee; Nam Hun Heo; Sang Mi Lee
Journal:  EJNMMI Res       Date:  2020-06-30       Impact factor: 3.138

3.  Low glucose metabolism in hepatocellular carcinoma with GPC3 expression.

Authors:  You-Cai Li; Chuan-Sheng Yang; Wen-Lan Zhou; Hong-Sheng Li; Yan-Jiang Han; Quan-Shi Wang; Hu-Bing Wu
Journal:  World J Gastroenterol       Date:  2018-01-28       Impact factor: 5.742

4.  Metabolic tumour volume on 18F-FDG PET/CT predicts extended pathological T stages in patients with renal cell carcinoma at staging.

Authors:  Dongwoo Kim; Narae Lee; Woong Kyu Han; Mijin Yun; Suk Hyun Lee; Hyun Jeong Kim; Hye-Suk Hong; Jee Soo Park; Nam-Hoon Cho; Young Deuk Choi; Won Sik Ham; Seung Hwan Lee
Journal:  Sci Rep       Date:  2021-12-06       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.